Skip to main content
. 2022 Jul 5;12:916437. doi: 10.3389/fcimb.2022.916437

Table 1.

Distribution of characteristics by study visit, N = 740 observations.

Visit Baseline, N = 218 n (%) 1 month, N = 197 n (%) 6 months, N = 169 n (%) 12 months, N = 156 n (%)
Male characteristics
Median age in years (IQR) 26 (24–30) 26.5 (24–30) 27 (24–30) 27 (24–30.75)
Educational attainment
Primary or less 92 (42.2) 85 (43.2) 76 (45.0) 74 (47.4)
Some secondary or more 126 (57.8) 112 (56.9) 93 (55.0) 82 (52.6)
Currently employed 173 (79.4) 150 (76.1) 124 (73.8) 107 (69.9)
Circumcised 121 (55.5) 115 (58.4) 98 (58.0) 86 (56.6)
HIV positive 25 (11.6) 22 (11.3) 21 (12.5) 19 (12.3)
HSV-2 positive 100 (46.1) 91 (46.4) 97 (57.4) 94 (60.6)
Genital ulcer disease, past 6 months (self-reported or clinician detected) 8 (3.8) 3 (1.5) 4 (2.4) 5 (3.3)
Median days since last sexual intercourse (IQR) 4 (3–8) 4 (3–8) 6.5 (3–8) 8 (3–9)
When washed penis after last sex
<1 h 49 (22.5) 48 (24.4) 47 (28.7) 49 (32.7)
1 h or more 169 (77.5) 149 (75.6) 117 (71.3) 101 (67.3)
Condom used at last sexual intercourse 36 (16.5) 36 (18.4) 32 (19.1) 30 (19.6)
Condom frequency in the past 6 months
Never 134 (61.5) 122 (61.9) 105 (62.5) 98 (64.1)
Sometimes 69 (31.6) 63 (32.0) 52 (31.0) 45 (29.4)
Always 15 (6.9) 12 (6.1) 11 (6.5) 10 (6.5)
Number of sex partners in the past 6 months
One 161 (74.9) 149 (76.4) 136 (85.0) 112 (78.3)
Two or more 54 (25.1) 46 (23.6) 24 (15.0) 31 (21.7)
Alpha diversity metrics, median (IQR)
Shannon diversity index 1.86 (1.36–2.17) 1.80 (1.43–2.22) 1.80 (1.44–2.19) 1.77 (1.34–2.16)
Simpson diversity 0.76 (0.65–0.84) 0.76 (0.65–0.84) 0.76 (0.66–0.83) 0.75 (0.59–0.83)
Evenness 0.60 (0.50–0.68) 0.60 (0.52–0.69) 0.60 (0.48–0.68) 0.58 (0.46–0.66)
Richness 23 (16–27) 22 (16.5–27.5) 23 (17–28.5) 22 (18–28)
Community type (CT)
CT-1 mixed 48 (22.0) 51 (25.9) 53 (31.4) 56 (35.9)
CT-2 Corynebacterium dominated 42 (19.3) 37 (18.8) 21 (12.4) 26 (16.7)
CT-3 Streptococcus dominated 19 (8.7) 14 (7.1) 12 (7.1) 13 (8.3)
CT-4 Sneathia sanguinegens dominated 33 (15.4) 28 (14.2) 19 (11.2) 14 (9.0)
CT-5 Finegoldia/Anaerococcus dominated 39 (17.9) 35 (17.8) 32 (18.9) 24 (15.4)
CT-6 Lactobacillus iners dominated 15 (6.9) 17 (8.6) 18 (10.6) 9 (5.8)
CT-7 Clostridiales family XII dominated 22 (10.1) 15 (7.6) 14 (8.3) 14 (9.0)
Female partner characteristics
Median age in years (IQR) 22 (20–25) 22.5 (20–25) 23 (20–25) 23 (20–25)
Bacterial vaginosis (Nugent score 7–10) 43 (20.2) 44 (22.5) 41 (27.0) 32 (26.5)
Documented treatment for BV 40 (93.0) 41 (93.0) 39 (95.1) 27 (84.4)
Vaginal discharge 67 (31.2) 53 (27.0) 41 (26.8) 33 (26.0)
HIV positive 22 (10.2) 19 (9.7) 21 (13.2) 19 (14.8)
HSV-2 positive 121 (55.5) 108 (54.8) 101 (63.1) 88 (68.2)
Genital ulcer disease, past 6 months (self-reported or clinician detected) 23 (10.7) 6 (3.1) 7 (4.6) 5 (3.9)
Community state type
I: Lactobacillus crispatus dominated 18 (8.5) 22 (12.0) 14 (9.2) 17 (13.3)
II: Lactobacillus jensenii dominated 2 (0.9) 1 (0.5) 2 (1.3) 1 (0.8)
III: Lactobacillus iners dominated 93 (43.7) 80 (43.7) 62 (40.8) 47 (36.7)
IV: Gardnerella vaginalis dominated 99 (46.5) 79 (43.2) 71 (46.7) 61 (47.7)
V: Lactobacillus gasseri dominated 1 (0.5) 1 (0.5) 3 (2.0) 2 (1.6)
Pregnant (urine HCG positive) 23 (10.7) 24 (12.2) 26 (16.6) 11 (8.9)
Contraceptive use
Implant 62 (28.4) 57 (28.9) 50 (31.5) 41 (32.3)
Injectable 40 (18.4) 35 (17.8) 27 (17.8) 28 (22.1)
Median (IQR) days since last menstrual period among non-pregnant women 25 (10.5–52) 17 (6–42) 19.5 (7.25–42.75) 19 (7–49.25)
Median (IQR) days since last menstrual period among non-pregnant women, not using hormonal contraceptives 20 (10–36) 15 (4–30) 15 (6–29) 13.5 (5.75–31.25)

IQR, interquartile range; HSV-2, herpes simplex virus type 2; HCG, human chorionic gonadotropin; BV, bacterial vaginosis.